The estimated Net Worth of Eric Aguiar is at least $2.12 Milión dollars as of 16 December 2020. Eric Aguiar owns over 10,000 units of BridgeBio Pharma Inc stock worth over $279,900 and over the last 9 years he sold BBIO stock worth over $135,000. In addition, he makes $1,703,900 as Independent Director at BridgeBio Pharma Inc.
Sign up
Eric Aguiar BBIO stock SEC Form 4 insiders trading
Eric has made over 15 trades of the BridgeBio Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of BBIO stock worth $241,600 on 16 December 2020.
The largest trade he's ever made was buying 1,103,848 units of BridgeBio Pharma Inc stock on 24 May 2019 worth over $28,622,779. On average, Eric trades about 52,690 units every 36 days since 2015. As of 16 December 2020 he still owns at least 10,000 units of BridgeBio Pharma Inc stock.
You can see the complete history of Eric Aguiar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eric Aguiar biography
Dr. Eric Aguiar M.D. serves as Independent Director of the Company. Dr. Aguiar has been a partner at Aisling Capital since January 2016 and prior to that was a partner at Thomas, McNerney and Partners, a healthcare venture capital and growth equity fund, since 2007. Prior to joining that firm, he was a Managing Director of HealthCare Ventures, a healthcare focused venture capital firm, from 2001 to 2007. Dr. Aguiar currently serves on the board of directors of Invitae Corporation (NYSE: NVTA) since September 2010 and Eidos Therapeutics (Nasdaq: EIDX) since March 2018. He served on the board of directors of Biohaven Corporation (NYSE: BHVN) from October 2016 to January 2020. Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. Dr. Aguiar received his medical degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst. Dr. Aguiar’s qualifications to serve on our Board of Directors include his medical and finance background and experience as an investor in life science companies.
What is the salary of Eric Aguiar?
As the Independent Director of BridgeBio Pharma Inc, the total compensation of Eric Aguiar at BridgeBio Pharma Inc is $1,703,900. There are 4 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.
How old is Eric Aguiar?
Eric Aguiar is 58, he's been the Independent Director of BridgeBio Pharma Inc since 2019. There are 10 older and 12 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
What's Eric Aguiar's mailing address?
Eric's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Insiders trading at BridgeBio Pharma Inc
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo a Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
What does BridgeBio Pharma Inc do?
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
What does BridgeBio Pharma Inc's logo look like?
Complete history of Eric Aguiar stock trades at Biohaven Ltd, Invitae Corp, Eidos Therapeutics Inc a BridgeBio Pharma Inc
BridgeBio Pharma Inc executives and stock owners
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:
-
Neil Kumar,
Chief Executive Officer, Director -
Charles Homcy,
Chairman of Pharmaceuticals, Lead Director -
Uma Sinha,
Chief Scientific Officer -
Brian Stephenson,
Chief Financial Officer -
Eric Aguiar,
Independent Director -
Ali Satvat,
Independent Director -
Jennifer Cook,
Independent Director -
Dr. Neil Kumar Ph.D.,
Co-Founder, CEO & Director -
Dr. Brian C. Stephenson C.F.A., Ph.D.,
CFO, Sec. & Principal Accounting Officer -
James Momtazee,
Independent Director -
Richard Scheller,
Chairman of Research and Development, Director -
Dr. Michael Thomas Henderson M.D.,
Chief Bus. Officer -
Dr. Charles J. Homcy M.D.,
Chairman of Pharmaceuticals & Lead Director -
Dr. Richard H. Scheller Ph.D.,
Chairman of R&D and Director -
Dr. Cameron Turtle DPHIL, Ph.D.,
Chief Strategy Officer -
Randal Scott,
Independent Director -
Brenton Saunders,
Independent Director -
Andrew Lo,
Independent Director -
Ronald Daniels,
Independent Director -
Michael Henderson,
Chief Business Officer -
Cameron Turtle,
Senior Vice President - Portfolio Management and Corporate Development -
Frank Mccormick,
Chairman of Oncology -
Dr. Frank McCormick Ph.D.,
Chairman of Oncology -
Grace Rauh,
VP of Communications -
Dr. Uma Sinha Ph.D.,
Chief Scientific Officer -
Yi Ching Yau,
Chief Accounting Officer -
Genetic Disorder L.P.Kkr Ge...,
-
Management Holdings L.P.Kkr...,
-
Douglas A. Dachille,
-
Fred Hassan,
-
Global Performance Llc Viki...,
-
Global Investors Lp Viking ...,
-
Genetic Disorder L.P.Robert...,
-
Yi Ching Yau,
Chief Accounting Officer -
Brian M. Stolz,
Chief Operating Officer -
Hannah Valantine,
-
Brent L Saunders,
Director -
Andrea Ellis,
-
Global Investors Lp Viking ...,
-
Thomas Trimarchi,
President and COO